健脾益肾补血法对晚期非小细胞肺癌化疗患者无进展生存期及1年生存率干预的临床研究

摘要

目的研究中药健脾益肾补血法对晚期非小细胞肺癌（NSCLC）患者无进展生存期（TTP）及1年生存率的影响。方法将120例肺癌化疗患者按随机数字表法分为对照组及观察组，每组60例。对照组采用吉西他滨+顺铂（GP方案）化疗方案，观察组在化疗期间每日服用1剂通补三升汤（组成：红参10 g，穿山甲10 g，山茱萸12 g，茜草30 g，鹿角胶10 g，熟地黄20 g，黄芪40 g，当归12 g，鸡内金10 g），连服21 d为1个周期。化疗结束后进行电话随访，截止时间为2012年8月30日。观察两组临床疗效、TTP和1年生存率。结果观察组和对照组有效率比较差异无统计学意义〔35.0%比36.7%，P＞0.05〕，但观察组TTP（月）明显长于对照组（5.21±0.31比4.29±0.25，P＜0.05），且1年生存率也明显高于对照组（45.0%比26.7%，P＜0.05）。结论中药健脾益肾补血法虽然不能提高NSCLC患者的有效率，但能够延长晚期NSCLC化疗患者的肿瘤TTP，并能提高1年生存率。%　　Objective To investigate the efficacy of invigorating spleen and kidney therapy on improving time to progression(TTP)and 1-year survival rate for patients with chemotherapy due to advanced non-small-cell lung cancer(NSCLC). Methods One hundred and twenty patients with advanced NSCLC were divided into control group and trial group by random number table,60 cases being in each group. The control group was treated only by gemcitabine and cisplatin regimen(GP),while the trial group was treated by gemcitabine and cisplatin regimen(GP) and received concurrently the oral administration of decoction for invigorating spleen and kidney therapy(including ingredients:ginseng rubra 10 g,pangolin scales 10 g,fructus corni 12 g,madder root 30 g,colla cornus cervi 10 g, prepared rehmannia root 20 g,astragalus root 40 g,angelica sinensis 12 g,ventriculi galli mucosa 10 g),one dose per day for consecutive 21 days constituting 1 therapeutic course. Follow-up by telephone was carried out after the end of chemotherapy,the expiration date was August 30,2012. The clinical effect,TTP and 1-year survival rate were observed. Results There was no significant difference in the objective efficiency between the two groups(effective power:35.0%vs. 36.7%,P>0.05). TTP in trial group was longer than that in control group(months:5.21±0.31 vs. 4.29±0.25,P<0.05),and 1-year survival rate in trial group was also higher than that in control group significantly (45.0% vs. 26.7%,P<0.05). Conclusion Invigorating spleen and kidney therapy can not improve the objective efficiency,but can improve TTP and 1-year survival rate for patients with advanced NSCLC who receive chemotherapy.